Innate Pharma Files 6-K Report
Ticker: IPHYF · Form: 6-K · Filed: Oct 15, 2025 · CIK: 1598599
| Field | Detail |
|---|---|
| Company | Innate Pharma SA (IPHYF) |
| Form Type | 6-K |
| Filed Date | Oct 15, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: filing, press-release, foreign-issuer
TL;DR
Innate Pharma filed a 6-K, likely with a press release attached. Check for updates.
AI Summary
On October 13, 2025, Innate Pharma S.A. filed a Form 6-K report with the SEC. This filing includes a press release dated October 14, 2025, as Exhibit 99.1. Innate Pharma S.A. is a French biopharmaceutical company focused on oncology.
Why It Matters
This filing provides an update from Innate Pharma S.A., a publicly traded company, which may contain important information for investors regarding its operations or strategic developments.
Risk Assessment
Risk Level: low — This is a routine filing (6-K) that typically contains press releases or other periodic information, not usually indicative of immediate high risk.
Key Players & Entities
- Innate Pharma S.A. (company) — Registrant
- October 14, 2025 (date) — Date of Press Release
- October 13, 2025 (date) — Date of Report
- 001-39084 (other) — SEC File Number
FAQ
What is the primary purpose of a Form 6-K filing?
A Form 6-K is filed by foreign private issuers to provide information that is made public, filed, or made available to their shareholders in their home country, or that is required to be filed with or is made available by a stock exchange on which they are listed.
What specific document is included as an exhibit in this 6-K filing?
Exhibit 99.1 is a Press Release dated October 14, 2025.
What is the filing date of this Form 6-K?
The filing date of this Form 6-K is October 15, 2025.
What is the principal executive office address of Innate Pharma S.A.?
The principal executive office address is 117 Avenue de Luminy—BP 30191, 13009 Marseille, France.
Does Innate Pharma S.A. file annual reports under Form 20-F?
Yes, Innate Pharma S.A. indicates that it files annual reports under Form 20-F.
Filing Stats: 158 words · 1 min read · ~1 pages · Grade level 9.8 · Accepted 2025-10-15 06:15:11
Filing Documents
- a6k-iphx251014.htm (6-K) — 8KB
- exhibit991-251014.htm (EX-99.1) — 22KB
- 0001628280-25-045045.txt ( ) — 32KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INNATE PHARMA S.A. Date October 13, 2025 By s JONATHAN DICKINSON Name Jonathan Dickinson Title Chief Executive officer